2023. Secukinumab in Moderate to Severe Hidradenitis Suppurativa: Primary Endpoint Analysis From the SUNSHINE and SUNRISE Phase 3 Trials. SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s129. DOI:https://doi.org/10.25251/skin.7.supp.129.